Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Yuling Xiao; Jiang Chen; Hui Zhou; Xiaodong Zeng; Zhiping Ruan; Zhangya Pu; Xingya Jiang; Aya Matsui; Lingling Zhu; Zohreh Amoozgar; Dean Shuailin Chen; Xiangfei Han; Dan G. Duda; Jinjun Shi

doi:10.1038/s41467-022-28279-8

Nature Communications (Feb 2022)

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Yuling Xiao,
Jiang Chen,
Hui Zhou,
Xiaodong Zeng,
Zhiping Ruan,
Zhangya Pu,
Xingya Jiang,
Aya Matsui,
Lingling Zhu,
Zohreh Amoozgar,
Dean Shuailin Chen,
Xiangfei Han,
Dan G. Duda,
Jinjun Shi

Affiliations

Yuling Xiao: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Jiang Chen: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Hui Zhou: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Xiaodong Zeng: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Zhiping Ruan: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Zhangya Pu: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Xingya Jiang: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Aya Matsui: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Lingling Zhu: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Zohreh Amoozgar: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Dean Shuailin Chen: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Xiangfei Han: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School
Dan G. Duda: Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
Jinjun Shi: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-022-28279-8
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

The p53 tumor suppressor gene is frequently mutated in liver cancer. Here the authors show that restoration of p53 expression with a mRNA nanoparticle platform elicits anti-tumor immune responses and promotes response to immune checkpoint blockade in preclinical models of p53-null hepatocellular carcinoma.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal